Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Digital Health M & A Business Strategies

Otsuka Rescues Fallen Unicorn Proteus Digital

Bankrupt US Venture To Support Digital Push

  • Analysis

Executive Summary

Japanese firm picks up struggling US venture for a fraction of its one-time value as it continues strategic push into the digital health space.

You may also be interested in...



Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs

During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.

BI Finds Right Fit For Digital Therapeutic Partnership With Click

Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m. 

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Table

View full table

Topics

Related Companies

Tags:
Digital Health M & A Business Strategies
Latest Headlines

Novartis Excited About Iptacopan But Downcast After Huntington’s Blow

Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question

Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval

From Science To Commercialization: How Genexine Is Making The Shift

See All
UsernamePublicRestriction

Register

SC142854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By